Hemoadhican, a Tissue Adhesion Hemostatic Material Independent of Blood Coagulation
Advanced Healthcare Materials · 2023
DOI: 10.1002/adhm.202300705 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2023. Verfasst von Changchang Kong und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing, 210094, China. Hauptthemen laut MEDLINE: Hemostatics, Chitosan. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Uncontrolled hemorrhage is a leading cause of death, emphasizing the need for novel hemostatic agents. Here, a novel hemostatic polysaccharide hemoadhican (HD) is screened out by analyzing the rheological properties of screened material mixed blood sludges, which is prepared by mixing polysaccharide granules and whole blood to mimic the coagulation in vitro. HD is produced by a bacterial isolate Paenibacillus sp.1229, and the repeating units of HD are →)‐ α ‐L‐Rhap‐(1→3)‐ β ‐D‐Glcp‐(1→4)[4,6‐ethylidene‐ α ‐D‐Galp‐(1→4)‐ α ‐D‐Glcp‐(1→3)]‐ α ‐D‐Manp‐(1→. Compared to chitosan and celox, HD achieves more effective hemostasis in animal models with mouse and rat femoral arteries, rat carotid arteries, and rabbit femoral arteries. Especially, HD maintains an excellent hemostatic capability in animals with heparin‐induced hemorrhage diathesis. In vitro experiments show HD granules can quickly absorb a small amount of blood component to create a hemophobic blood sludge resistant to high pressure. The blood sludge firmly adheres to damaged tissue and efficiently repels blood. In vitro experiments show that HD does not actively trigger blood coagulation cascade and is independent of blood conditions including heparin treatment. In addition, HD moisturizes wounds and accelerates wound healing, exhibiting excellent biodegradability, and hemocompatibility. The results indicate that HD is a promising hemostatic material for treating traumatic hemorrhages and uncontrollable surgical bleeding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Molecular Metabolism, Nanjing University of Science & Technology, Nanjing, 210094, China.
- Key Laboratory of Metabolic Engineering and Biosynthesis Technology, Ministry of Industry and Information Technology, Beijing, 210094, China.
- Nanjing Southern Element Biotechnology Co., Ltd, Nanjing, 211899, China.
ORCID-Profile: Shijunyin Chen, Jianfa Zhang
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Kong, C., Chen, S., Wang, X., Hu, C., Li, B., Fu, R., & Zhang, J. (2023). Hemoadhican, a Tissue Adhesion Hemostatic Material Independent of Blood Coagulation. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202300705
Vancouver
Kong C, Chen S, Wang X, Hu C, Li B, Fu R, et al. Hemoadhican, a Tissue Adhesion Hemostatic Material Independent of Blood Coagulation. Advanced Healthcare Materials. 2023. doi:10.1002/adhm.202300705
BibTeX
@article{Kong2023,
author = {Kong, Changchang and Chen, Shijunyin and Wang, Xianjin and Hu, Chengtao and Li, Bing and Fu, Renjie and Zhang, Jianfa},
title = {Hemoadhican, a Tissue Adhesion Hemostatic Material Independent of Blood Coagulation},
journal = {Advanced Healthcare Materials},
year = {2023},
doi = {10.1002/adhm.202300705}
}
EUVIMED